Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab + pertuzumab + palbociclib + exemestane neoadjuvant therapy in HR+/HER2+ stage II–III breast cancer
ChiCTR2500104838Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab, pertuzumab, palbociclib and exemestane in breast cancer, sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: tpCR (total pathologic complete response rate). Planned start Jun 2025; status: not yet recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2500104838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500104838.